Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 known ✓ | P11362 | 2/20 | 0.47 |
| ▸ | HSP90AA1 known ✓ | P07900 | 1/20 | 0.46 |
| ▸ | PDGFRB known ✓ | P09619 | 1/20 | 0.42 |
| ▸ | PDGFRA known ✓ | P16234 | 1/20 | 0.42 |
| ▸ | ROCK2 known ✓ | O75116 | 1/20 | 0.42 |
| ▸ | PRKD3 known ✓ | O94806 | 1/20 | 0.42 |
| ▸ | ROCK1 known ✓ | Q13464 | 1/20 | 0.42 |
| ▸ | PIK3CA known ✓ | P42336 | 1/20 | 0.42 |
| ▸ | PIM1 | P11309 | 2/20 | 0.49 |
| ▸ | PIM3 | Q86V86 | 2/20 | 0.49 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | CDK2 | P24941 | 2/20 | 0.46 |
| ▸ | IDO1 | P14902 | 1/20 | 0.46 |
| ▸ | CLK1 | P49759 | 2/20 | 0.45 |
| ▸ | DYRK3 | O43781 | 2/20 | 0.45 |
| ▸ | CLK2 | P49760 | 2/20 | 0.45 |
| ▸ | GSK3B | P49841 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7068353 | 0.98 | PIM1 (0.50) | PIM1PIM3PIM2FGFR1NPC1 | |
| SCHEMBL31460000 | 0.98 | PIM1 (0.50) | PIM1PIM3PIM2FGFR1NPC1 | |
| SCHEMBL23884385 | 0.91 | HSP90AA1 (0.47) | PIM1PIM3PIM2FGFR1NPC1 | |
| SCHEMBL842550 | 0.77 | CHEK1 (0.52) | PIM1PIM3PIM2FGFR1RAB9A | |
| SCHEMBL150476 | 0.77 | NPC1 (0.65) | NPC1POLBRAB9AHSP90AA1DYRK1A | |
| SCHEMBL29350099 | 0.77 | NPC1 (0.65) | NPC1POLBRAB9AHSP90AA1DYRK1A | |
| SCHEMBL1572257 | 0.75 | HSP90AA1 (0.64) | FGFR1RAB9ACDK2HSP90AA1IDO1 | |
| SCHEMBL29680194 | 0.75 | HSP90AA1 (0.64) | FGFR1RAB9ACDK2HSP90AA1IDO1 | |
| Quinoline SCHEMBL9383866 | 0.74 | HSP90AA1 (0.68) | PIM1PIM3PIM2FGFR1NPC1 | |
| Hydrochloric Acid SCHEMBL8801533 | 0.74 | IDO1 (0.45) | PIM1PIM3PIM2FGFR1CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4367231-A | PARKINSON*S SYNDROME | ELI LILLY AND COMPANY (US) | 1983-01-04 | — | — | US | disclosed |
| EP-0050881-A1 | Octahydro quinoline derivatives | ELI LILLY AND COMPANY (US) | 1982-05-05 | — | — | EP | disclosed |
| US-4230861-A | DOPAMINE ANTAGONISTS | ELI LILLY AND COMPANY (US) | 1980-10-28 | — | — | US | disclosed |
| EP-0013787-A1 | Octahydro pyrazolo (3,4-g)quinolines, process for their preparation and pharmaceutical compositions containing them | ELI LILLY AND COMPANY (US) | 1980-08-06 | — | — | EP | disclosed |
| US-4198415-A | Prolactin inhibiting octahydro pyrazolo[3,4-g]quinolines | ELI LILLY AND COMPANY (US) | 1980-04-15 | — | — | US | disclosed |